{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T07:54:34Z","timestamp":1769154874652,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR000136"],"award-info":[{"award-number":["KL2 TR000136"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016866","name":"Henry J. Predolin Foundation for Research in Leukemia","doi-asserted-by":"publisher","award":["KL2 TR000136"],"award-info":[{"award-number":["KL2 TR000136"]}],"id":[{"id":"10.13039\/100016866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.mayocp.2015.11.011","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T11:02:50Z","timestamp":1454324570000},"page":"259-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Chronic Myelomonocytic Leukemia: Focus on Clinical Practice"],"prefix":"10.1016","volume":"91","author":[{"given":"Mrinal M.","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mayocp.2015.11.011_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.011_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ad\u00e8s","year":"2013","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.mayocp.2015.11.011_bib5","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.011_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2141.1994.tb06733.x","article-title":"Establishing the incidence of myelodysplastic syndrome","volume":"87","author":"Williamson","year":"1994","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2015.11.011_bib8","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.011_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.clml.2015.06.002","article-title":"Patients with therapy-related CMML have shorter median overall survival than those with de novo CMML: Mayo Clinic long-term follow-up experience","volume":"15","author":"Subari","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.011_bib10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.leukres.2011.05.003","article-title":"Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature","volume":"36","author":"Mathew","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.23962","article-title":"Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.011_bib13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.011_bib15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.mayocp.2015.11.011_bib17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.mayocp.2015.11.011_bib18","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4161\/cc.6.5.3919","article-title":"Oncogenes in myeloproliferative disorders","volume":"6","author":"Tefferi","year":"2007","journal-title":"Cell Cycle"},{"issue":"23","key":"10.1016\/j.mayocp.2015.11.011_bib22","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","article-title":"Francophone Myelodysplasia Group. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia","volume":"125","author":"Selimoglu-Buet","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2015.11.011_bib23","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1182\/blood-2010-02-258558","article-title":"Nomenclature of monocytes and dendritic cells in blood","volume":"116","author":"Ziegler-Heitbrock","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.011_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ajh.23548","article-title":"What is a promonocyte?","volume":"88","author":"Bain","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.011_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-015-0271-4","article-title":"Chronic myelomonocytic leukemia: a genetic and clinical update","volume":"10","author":"McCullough","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.011_bib29","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2015.11.011_bib31","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1038\/ncomms8307","article-title":"Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex","volume":"6","author":"Balasubramani","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.011_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.011_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/epi.7.2.19015","article-title":"Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia","volume":"7","author":"Yamazaki","year":"2012","journal-title":"Epigenetics"},{"issue":"18","key":"10.1016\/j.mayocp.2015.11.011_bib34","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood-2013-01-451781","article-title":"Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia","volume":"121","author":"Abdel-Wahab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"issue":"7325","key":"10.1016\/j.mayocp.2015.11.011_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.mayocp.2015.11.011_bib38","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2012-01-404863","article-title":"SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)","volume":"120","author":"Meggendorfer","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.011_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2011-09-377994","article-title":"SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value","volume":"119","author":"Patnaik","year":"2012","journal-title":"Blood"},{"issue":"7367","key":"10.1016\/j.mayocp.2015.11.011_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.mayocp.2015.11.011_bib41","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib42","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib43","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2015.11.011_bib44","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.011_bib45","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.011_bib46","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.011_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","article-title":"New prognostic parameters for chronic myelomonocytic leukemia","volume":"100","author":"Germing","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.011_bib48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.011_bib49","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.mayocp.2015.11.011_bib50","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","article-title":"Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet","volume":"122","author":"Malcovati","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23642","article-title":"Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","article-title":"Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis","volume":"87","author":"Moyo","year":"2008","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib54","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood-2004-10-3872","article-title":"Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF","volume":"106","author":"J\u00e4dersten","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.011_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ajh.24038","article-title":"Refractory anemia with ring sideroblasts and RARS with thrombocytosis","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib56","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bjh.13088","article-title":"Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials","volume":"167","author":"Prica","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1078155214544076","article-title":"Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia","volume":"21","author":"Modi","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2362.2007.01915.x","article-title":"Iron overload in myelodysplastic syndromes (MDS) \u2013diagnosis, management, and response criteria: a proposal of the Austrian MDS platform","volume":"38","author":"Valent","year":"2008","journal-title":"Eur J Clin Invest"},{"issue":"suppl 9","key":"10.1016\/j.mayocp.2015.11.011_bib59","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0082","article-title":"NCCN Task Force: transfusion and iron overload in patients with myelodysplastic syndromes","volume":"7","author":"Greenberg","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib60","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ajh.21192","article-title":"Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts","volume":"83","author":"Chee","year":"2008","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.21391","article-title":"Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not","volume":"84","author":"Tefferi","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib62","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/leu.2009.39","article-title":"Iron chelation therapy in myelodysplastic syndrome \u2013 Cui bono?","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib63","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.22001","article-title":"Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates","volume":"86","author":"Durairaj","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03630269.2011.578515","article-title":"Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome","volume":"35","author":"Cermak","year":"2011","journal-title":"Hemoglobin"},{"issue":"5","key":"10.1016\/j.mayocp.2015.11.011_bib65","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","article-title":"Clinical application of deferasirox: practical patient management","volume":"83","author":"Vichinsky","year":"2008","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib66","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A\u00a0randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia: Groupe Fran\u00e7ais des My\u00e9lodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib67","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s002770050569","article-title":"A\u00a0phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes","volume":"79","author":"Venditti","year":"2000","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib68","first-page":"1164","article-title":"All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study","volume":"10","author":"Cambier","year":"1996","journal-title":"Leukemia"},{"issue":"5-6","key":"10.1016\/j.mayocp.2015.11.011_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.011_bib70","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2015.11.011_bib71","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/cncr.22186","article-title":"Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"107","author":"Quintas-Cardama","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib72","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.11262","article-title":"Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes","volume":"92","author":"Siitonen","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.mayocp.2015.11.011_bib73","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/leu.2008.156","article-title":"On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.mayocp.2015.11.011_bib74","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.011_bib75","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.mayocp.2015.11.011_bib76","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Groupe Francophone des My\u00e9lodysplasies. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2015.11.011_bib77","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2015.11.011_bib78","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10428194.2012.719617","article-title":"High rate of remissions\u00a0in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study","volume":"54","author":"Fianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.mayocp.2015.11.011_bib79","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib80","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review","volume":"36","author":"Thorpe","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.011_bib81","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.mayocp.2015.11.011_bib82","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.mayocp.2015.11.011_bib83","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1038\/bcj.2015.9","article-title":"Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome","volume":"5","author":"Patnaik","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.mayocp.2015.11.011_bib84","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2015.11.011_bib85","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.mayocp.2015.11.011_bib86","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/bmt.2009.375","article-title":"Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience","volume":"45","author":"Krishnamurthy","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2015.11.011_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib88","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2015.11.011_bib89","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2008.366","article-title":"Outcome of allo-SCT for chronic myelomonocytic leukemia","volume":"43","author":"Ocheni","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.mayocp.2015.11.011_bib90","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1038\/bcj.2015.41","article-title":"ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26","volume":"5","author":"Perez Botero","year":"2015","journal-title":"Blood Cancer J"},{"issue":"S241","key":"10.1016\/j.mayocp.2015.11.011_bib91","article-title":"Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome","volume":"45","author":"Symeonidis","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2, suppl","key":"10.1016\/j.mayocp.2015.11.011_bib92","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.bbmt.2014.11.022","article-title":"Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia","volume":"21","author":"Duong","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.mayocp.2015.11.011_bib93","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A\u00a0decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2015.11.011_bib94","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.mayocp.2015.11.011_bib95","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie-Cellulaire and the Groupe-Francophone des My\u00e9lodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615009349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619615009349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T09:49:18Z","timestamp":1617616158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619615009349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0025619615009349"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.011","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myelomonocytic Leukemia: Focus on Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}